Vitroscope
Trondheim, Norway
◆ About Vitroscope
Biotech company developing automated perfusion platforms that maintain living tissue under controlled flow conditions for drug discovery and translational research.
◆ What sets it apart
Its integrated, closed-loop perfusion platforms maintain living human tissue and vascularised organoids under controlled physiological flow while supporting real-time imaging and experimental control.[2][3]
◆ Sectors
◆ Business
Modelhardware
CustomerPharmaceutical and biotechnology companies, academic researchers, and translational life-science laboratories conducting tissue, organoid, and drug-response studies
◆ Notable
- Raised $7 million comprising a $5 million seed round and $2 million in non-dilutive funding from the Research Council of Norway.[1]
- Developed vitro.alive and is validating the higher-throughput vitro.scale platform, with customer testing planned for 2027 and launch planned for 2028.[1]
◆ Funding rounds
◆ Explore the market
◆ FAQ
What does Vitroscope do?
Biotech company developing automated perfusion platforms that maintain living tissue under controlled flow conditions for drug discovery and translational research.
Where is Vitroscope based?
Vitroscope is based in Trondheim, Norway.
How much has Vitroscope raised?
Vitroscope has raised $7M in tracked funding and is currently at the seed stage.
Who has invested in Vitroscope?
Investors in Vitroscope include Cerberus Ventures, YZR Capital, Arcas Ventures, Golden Egg Check, Devico Invest and Research Council of Norway.